Comparative effectiveness of ceftolozane/tazobactam against pediatric gram-negative drug-resistant isolates.

TitleComparative effectiveness of ceftolozane/tazobactam against pediatric gram-negative drug-resistant isolates.
Publication TypeJournal Article
Year of Publication2021
AuthorsKanwar N, Banerjee D, Harrison CJ, Newland JG, Qin X, Zerr DM, Zaoutis T, Selvarangan R
JournalJ Chemother
Pagination1-6
Date Published2021 Mar 01
ISSN1973-9478
Abstract

Ceftolozane/tazobactam (C/T), a cephalosporin/beta-lactamase inhibitor combination, was evaluated vs. 10 comparators against 299 pediatric extended-spectrum-cephalosporin-resistant or carbapenem-resistant (ESC-R/CR) Gram-negative Enterobacteriaceae from three freestanding pediatric centers. Isolates were from urine or other sterile sites of children and adolescents through 21 years of age. Susceptibilities were assayed by microbroth dilution via custom Sensititre plates (Thermo Fisher Scientific). Susceptibility was determined using the Sensititre Vizion® system (Thermo Fisher Scientific). Susceptibility breakpoint criteria were those of the Clinical and Laboratory Standards Institute (CLSI) for 2017, except for colistin (EUCAST 2019). Overall, 87.5% isolates were C/T susceptible (MIC ≤2 μg/ml; MIC 0.25/4 μg/ml). Susceptibility to C/T was detected more frequently as compared to all other antimicrobials tested except for colistin (95.4%) and meropenem (97.4%). Percent susceptibility to C/T was high for (91%) and . (73.3%). C/T demonstrated good activity and high potency against most beta-lactam resistant pediatric Enterobacteriaceae from three geographically diverse U.S. regions.

DOI10.1080/1120009X.2021.1888030
Alternate JournalJ Chemother
PubMed ID33645447